More Apellis Pharmaceuticals, Inc. news Apellis Pharmaceuticals, Inc.NASDAQ: APLS Positive top-line results from the phase 3 PRINCE study of pegcetacoplan in treatment-naïve patients with PNH May 25, 2021 · Issued by Apellis Pharmaceuticals, Inc. As issuedPlain English Watch Apellis Pharmaceuticals explain it↗Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call · Replay · Feb 24- Pegcetacoplan demonstrated statistical superiority on the co-primary endpoints of haemoglobin stabilisation (p
